Scienture Holdings, Inc. - 10-Q Filing
Scienture Holdings, Inc. reports Q3 2026 financial results featuring pharmaceutical product resale revenue and ongoing R&D for SCN102 and Naloxone HCl nasal spray.
Scienture Holdings, Inc. reports Q3 2026 financial results featuring pharmaceutical product resale revenue and ongoing R&D for SCN102 and Naloxone HCl nasal spray.